Table 2.
Characteristics of primary disease (pancreatic carcinoma)
| FAS (N = 270) | SAF (N = 338) | ||
|---|---|---|---|
| Time from diagnosis of primary tumor until informed consent [days] | n (number of patients) | 270 | 338 |
| Mean (SD) | 168 (300) | 174 (332) | |
| Median (Min, Max) | 36 (1, 2199) | 37 (1, 2383) | |
| Time from occurrence of metastases until informed consent [days] | n (number of patients) | 265 | 333 |
| Mean (SD) | 71 (119) | 78 (170) | |
| Median (Min, Max) | 27 (1, 792) | 29 (1, 2383) | |
| Localization of primary tumor [n (%)] a,b | Head of pancreas | 157 (58.1) | 190 (56.2) |
| Tail of pancreas | 63 (23.3) | 73 (21.6) | |
| Body of pancreas | 59 (21.9) | 72 (21.3) | |
| Other | 10 (3.7) | 17 (5.0) | |
| Localization of metastases [n (%)] b,c | Liver | 162 (60.7) | 199 (60.5) |
| Lymph nodes | 71 (26.6) | 83 (25.2) | |
| Peritoneum | 46 (17.2) | 56 (17.0) | |
| Lung | 42 (15.7) | 51 (15.5) | |
| Other | 53 (19.9) | 64 (19.5) | |
| Tumor stage according to UICC [n (%)] a | IV (any T, any N, M1) | 219 (81.1) | 274 (81.1) |
| III (T4, any N, M0) | 4 (1.5) | 5 (1.5) | |
| IIb (T1-T3, N1, M0) | 12 (4.4) | 15 (4.4) | |
| IIa (T3, N0, M0) | 2 (0.7) | 2 (0.6) | |
| Ib (T2, N0, M0) | 1 (0.4) | 1 (0.3) | |
| NA | 32 (11.9) | 41 (12.1) | |
| Tumor histology [n (%)] a | Adenocarcinoma | 249 (92.2) | 306 (90.5) |
| Papillary carcinoma | 0 | 1 (0.3) | |
| Other | 8 (3.0) | 11 (3.3) | |
| Not performed | 14 (5.2) | 21 (6.2) | |
| Biliary stent [n (%)] a | No | 212 (78.5) | 266 (78.7) |
| Yes | 58 (21.5) | 72 (21.3) | |
aPercentages are based on the total number of patients in each analysis set
bMultiple localizations of primary tumor and/or metastases were possible per patient
cPercentages are based on patients with data on localization of metastases available (FAS: n = 267; SAF: n = 329)
M distant metastasis, N regional lymph node, NA not available, T primary tumor, UICC Union for International Cancer Control